Ryan Paul will present a practical guide around experiences with dulaglutide, the newly funded subcutaneous once weekly GLP1 receptor agonist for type 2 diabetes.
Key topics include:
- Identifying which of your patients will benefit from dulaglutide.
- Which patients meet the special authority criteria for dulaglutide and who should consider self-funding.
- When to choose dulaglutide or empagliflozin or both.
- How to discuss starting dulaglutide with patients and how to manage any adverse effects.
- Recommended follow up for patients on dulaglutide.
- Management Algorithm For Type 2 Diabetes New Zealand Society for the Study of Diabetes
- Initiating treatment with dulaglutide in adult patients with type 2 diabetes He Ako Hiringa
- Dulaglutide patient information Health Navigator New Zealand
BHB MBChB (Auckland) FRACP, PhD
Ryan Paul is an endocrinologist and diabetologist at the Waikato District Health Board. He is active in research in his roles as a Senior Lecturer at the University of Waikato and as a Clinical Associate of the Maurice Wilkins Centre. He also has a key role in teaching as a member of the Royal Australasian College of Physicians (RACP) Training Committees and with Diabetes Nurse Prescribers in New Zealand, and was awarded the New Zealand Clinical Educator of the Year by the New Zealand Medical Council in 2019.
Ryan is also the current President of the New Zealand Society of Endocrinology (NZSE) and an Executive Member of the New Zealand Society for the Study of Diabetes (NZSSD). He recently convened the new NZSSD national guidance on the management of type 2 diabetes.